Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Current Liabilities (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Total Current Liabilities readings, the most recent being $21.2 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 2.32% to $21.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.2 million, a 2.32% decrease, with the full-year FY2025 number at $21.2 million, down 2.32% from a year prior.
  • Total Current Liabilities hit $21.2 million in Q4 2025 for Aligos Therapeutics, down from $22.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $41.4 million in Q1 2022 to a low of $18.9 million in Q1 2024.
  • Median Total Current Liabilities over the past 5 years was $24.6 million (2021), compared with a mean of $26.7 million.
  • Biggest five-year swings in Total Current Liabilities: surged 63.91% in 2022 and later crashed 32.76% in 2024.
  • Aligos Therapeutics' Total Current Liabilities stood at $39.0 million in 2021, then decreased by 14.96% to $33.1 million in 2022, then decreased by 27.84% to $23.9 million in 2023, then fell by 9.07% to $21.7 million in 2024, then dropped by 2.32% to $21.2 million in 2025.
  • The last three reported values for Total Current Liabilities were $21.2 million (Q4 2025), $22.0 million (Q3 2025), and $20.3 million (Q2 2025) per Business Quant data.